Top Pfizer Shareholders

Pfizer Inc. (PFE) is a multinational pharmaceutical and biotechnology company. It researches, develops, and manufactures biopharmaceutical products across a range of different areas, including oncology, cardiovascular disease, inflammatory diseases, immunology, rare diseases, and vaccines. In collaboration with BioNTech SE (BNTX), a German-based biotechnology company, Pfizer developed an mRNA-based vaccine against COVID-19. The Pfizer-BioNTech vaccine has been administered to millions of people in the U.S. and abroad, and sales may increase further as the U.S. and other nations administer booster shots to further protect people from the virus.

The top shareholders of Pfizer are Frank A. D’amelio, John Douglas Young, Mikael Dolsten, Vanguard Group Inc., BlackRock Inc. (BLK), and State Street Corp. (STT).

On Aug. 23, 2021, the U.S. Food and Drug Administration (FDA) approved the Pfizer-BioNTech COVID-19 vaccine, which is now being marketed as Comirnaty. Previously, the vaccine was only approved under emergency use authorization (EUA). It became the first vaccine against COVID-19 to gain full approval from the FDA. The vaccine continues to be available under EUA, including for individuals between the ages of 12 and 15.

Pfizer’s 12-month trailing net income and revenue are $13.2 billion and $51.6 billion, respectively. The company’s market cap is about $248.4 billion. These financial data are as of Sept. 16, 2021.

Top 3 Individual Insider Shareholders

The shares owned by individual insider shareholders are those that are held through direct ownership. Shares mentioned in this section do not include shares held indirectly nor shares accessible through stock options. Company insiders must file an SEC Form 4 every time they buy or sell an amount of the company’s stock that is deemed to be material.

Frank A. D’amelio

Frank A. D’amelio owns a total of 483,188 Pfizer shares, representing 0.01% of the company’s total shares outstanding. D’amelio is chief financial officer (CFO) and executive vice president of Global Supply. He oversees the company’s corporate finance functions, which include audit, treasury, tax, insurance, business finance and analytics, and more. D’amelio was responsible for leading Pfizer’s acquisition of Wyeth Pharmaceuticals, King Pharmaceuticals, Hospira Inc., Anacor Pharmaceuticals Inc., and Medivation Inc. He also led the spinoff of Zoetis, the company’s animal health business, as well as the sale of its nutrition business. Before joining Pfizer in 2007, D’amelio worked for Alcatel-Lucent as chief administrative officer and senior executive vice president of Integration.

John Douglas Young

John Douglas Young owns a total of 461,761 Pfizer shares, representing 0.01% of the company’s total shares outstanding. Young has been with Pfizer for more than 30 years and is the company’s group president and chief business officer. Prior to his current role, he was group president of Pfizer Innovative Health, which included six separate business units focused on developing innovative medicines and vaccines. Young was also responsible for expanding Pfizer’s footprint in emerging markets in Latin America, Asia, Africa, and the Middle East. Before that, he was group president for Pfizer Essential Health. Young also serves as a member of the board of directors of the Consumer Healthcare joint venture with GlaxoSmithKline PLC (GSK), as well as on the board of Johnson Controls International PLC (JCI).

Mikael Dolsten

Mikael Dolsten owns a total of 137,727 Pfizer shares, representing fewer than 0.01% of the company’s total shares outstanding. Dolsten is Pfizer’s chief scientific officer and president of Worldwide Research, Development and Medical (WRDM). His focus is on developing scientific breakthroughs in small-molecule medicines, biotherapeutics, gene therapies, and vaccines. As president of WRDM, Dolsten oversees all of Pfizer’s research units, including Oncology, Internal Medicine, Inflammation & Immunology, Vaccines, Rare Disease, and the Centers for Therapeutic Innovation. Before joining Pfizer in 2009, he served as the president of Wyeth Research, and before that, as executive vice president and head of Worldwide Research at Boehringer Ingelheim. Dolsten is the inventor on several patents and has published approximately 150 articles in international journals.

Top 3 Institutional Shareholders

Institutional investors hold between 65-66% of Pfizer’s total shares outstanding.

Vanguard Group Inc.

Vanguard Group owns 456.2 million shares of Pfizer, representing 8.1% of total shares outstanding, according to the company’s 13F filing for the period ending June 30, 2021. The company is primarily a mutual fund and ETF management company with about $7.2 trillion in global assets under management (AUM). The Vanguard S&P 500 ETF (VOO) is one of the company’s largest exchange-traded funds (ETFs) with about $256 billion in AUM. Pfizer comprises nearly 0.7% of VOO’s holdings.

BlackRock Inc.

BlackRock owns 407.0 million shares of Pfizer, representing 7.3% of total shares outstanding, according to the company’s 13F filing for the period ending June 30, 2021. The company is primarily a mutual fund and ETF management company with approximately $8.7 trillion in AUM. The iShares Core S&P 500 ETF (IVV) is among one of BlackRock’s largest ETFs with approximately $305 billion in AUM. Pfizer comprises nearly 0.7% of IVV’s holdings.

State Street Corp.

State Street owns 278.6 million shares of Pfizer, representing 5.0% of total shares outstanding, according to the company’s 13F filing for the period ending June 30, 2021. The company is primarily a manager of mutual funds, ETFs and other assets with approximately $3.9 trillion in AUM. The SPDR S&P 500 ETF Trust (SPY) is among one of State Street’s largest ETFs with approximately $410 billion in AUM. Pfizer comprises nearly 0.7% of SPY’s holdings.

View Article Origin Here